Wang Yue, Wu Chenchen, Liu Yanan, Lou Youpan, Chen Cheng, Chen Qianqian, Li Xihan, Ma Chao, Li Jing, Huang Ying
Department of Pain, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
CNS Neurosci Ther. 2025 May;31(5):e70460. doi: 10.1111/cns.70460.
Postherpetic neuralgia (PHN) is the most common chronic complication of herpes zoster (HZ), and current treatment regimens often fail to effectively control the pain.
The purpose of this study is to compare the efficacy and tolerability of duloxetine combined with pregabalin and amitriptyline combined with pregabalin in the treatment of PHN, as well as their impact on sleep and quality of life in patients with PHN.
This is a double-blind, randomized, crossover trial involving PHN patients. About 220 participants were randomly assigned (1:1) to either the duloxetine combined with pregabalin or the amitriptyline combined with pregabalin. The patient takes duloxetine or amitriptyline orally before bedtime for 6 weeks each time. Perform a 2-week single-blind placebo washout between the two treatments, and a 2-week single-blind placebo washout at the end of the treatment period. In the last week of the treatment cycle, evaluate the 7-day average daily pain, Pittsburgh Sleep Quality Index, 17-item Hamilton Depression Rating Scale, 36-Item Short Form Health Survey, and record the occurrence of major adverse events. A median reduction of 50%, 25%-50%, and 25% in pain score is considered good, moderate, and mild improvement, respectively.
Both treatment methods can significantly improve the baseline pain value (p < 0.001 for both). The combination of duloxetine and pregabalin resulted in good, moderate, and mild pain relief of 52%, 24%, and 7%, respectively. The combination of amitriptyline and pregabalin resulted in good, moderate, and mild pain relief of 48%, 21%, and 9%, respectively. There was no significant difference in the measurement of various results between the two groups. In the reported adverse events, patients in the amitriptyline group had significantly more dry mouth compared to the duloxetine group (26% vs. 11%; p = 0.008).
Duloxetine and amitriptyline have similar analgesic effects, and the difference is not statistically significant. The combination of pregabalin has good tolerability and better pain relief in PHN patients, thus providing clinically relevant benefits.
Chinese Clinical Trial Registry: ChiCTR2100054831.
带状疱疹后神经痛(PHN)是带状疱疹(HZ)最常见的慢性并发症,目前的治疗方案往往无法有效控制疼痛。
本研究旨在比较度洛西汀联合普瑞巴林与阿米替林联合普瑞巴林治疗PHN的疗效和耐受性,以及它们对PHN患者睡眠和生活质量的影响。
这是一项涉及PHN患者的双盲、随机、交叉试验。约220名参与者被随机分配(1:1)至度洛西汀联合普瑞巴林组或阿米替林联合普瑞巴林组。患者每次在睡前口服度洛西汀或阿米替林,持续6周。在两种治疗之间进行为期2周的单盲安慰剂洗脱期,在治疗期结束时进行为期2周的单盲安慰剂洗脱期。在治疗周期的最后一周,评估7天平均每日疼痛、匹兹堡睡眠质量指数、17项汉密尔顿抑郁量表、36项简明健康调查,并记录主要不良事件的发生情况。疼痛评分中位数降低50%、25%-50%和25%分别被认为是良好、中度和轻度改善。
两种治疗方法均能显著改善基线疼痛值(两者p均<0.001)。度洛西汀与普瑞巴林联合使用导致良好、中度和轻度疼痛缓解的比例分别为52%、24%和7%。阿米替林与普瑞巴林联合使用导致良好、中度和轻度疼痛缓解的比例分别为48%、21%和9%。两组之间各项结果的测量无显著差异。在报告的不良事件中,阿米替林组患者口干的发生率显著高于度洛西汀组(26%对11%;p=0.008)。
度洛西汀和阿米替林具有相似的镇痛效果,差异无统计学意义。联合普瑞巴林对PHN患者具有良好的耐受性和更好的疼痛缓解效果,从而提供临床相关益处。
中国临床试验注册中心:ChiCTR2100054831。